On November 6, 2026 Servier reported that it will present nine abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, November 12-15 in Philadelphia. The data span Servier’s growing glioma portfolio and include clinical and real-world data for VORANIGO (vorasidenib) in IDH-mutant glioma, as well as recently released four-year data from the Phase 2 FIREFLY-1 study of OJEMDA (tovorafenib) in relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"By expanding the scope of clinical and real-world evidence supporting the safety and efficacy of VORANIGO and OJEMDA, we are deepening our understanding of these complex diseases and generating insights that will help us deliver meaningful treatment advances for people living with glioma," said Islam Hassan, M.D., MSc., Global Head of Development, Neuro-Oncology at Servier. "Our robust body of data at SNO underscores Servier’s leadership in glioma and our commitment to advancing targeted therapies for adults and children living with significant unmet needs."
Evaluating long-term outcomes in pLGG
An oral presentation will highlight OJEMDA data in pLGG:
Updated results from the four-year follow-up analysis of the Phase 2 FIREFLY-1 study will be presented, including data on post-treatment observation and retreatment with OJEMDA following disease progression in patients with relapsed or refractory BRAF-altered pLGG.
Building on the clinical evidence in IDH-mutant glioma
Two oral presentations will feature analyses from the Phase 3 INDIGO trial:
Extended follow-up (median overall duration of 41.6 months) data from patients with Grade 2 IDH-mutant glioma randomized to receive VORANIGO, including subgroup analyses of histological subtype, will be presented. The results demonstrate sustained, long-term clinical benefits of VORANIGO in Grade 2 IDH-mutant glioma regardless of prognostic factors.
A separate analysis suggests long-term treatment with VORANIGO generally led to a sustained decrease in seizure activity and delayed worsening of quality of life in patients with IDH-mutant glioma.
Exploring potential beyond the INDIGO population
Two oral presentations will highlight retrospective observational analyses of real-world utilization of VORANIGO in Grade 2 and Grade 3 IDH-mutant glioma:
Analyses of time to next intervention (TTNI) among 499 patients with Grade 2 IDH-mutant glioma demonstrated short-term real-world effectiveness of VORANIGO. The highest rate was observed among frontline VORANIGO users.
An analysis of a cohort of 80 Grade 3 mIDH glioma patients showed emerging evidence of the effectiveness of VORANIGO in these patients.
These data collectively reflect Servier’s continued investment in advancing glioma research. A full list of Servier abstracts and presentation details for SNO 2026 can be found here.
(Press release, Servier, NOV 6, 2026, View Source [SID1234674397])